Otros idiomas EyePoint Pharmaceuticals, Inc. Deutsche Boerse AG

Acciones

PV3B

US30233G2093

Tiempo real estimado Tradegate Otros sitios de cotización 14:35:49 10/06/2024			Varia. Cinco días.	Varia. 1 de enero.
8,45 ^EUR	-0,42 %		-14,99 %	-60,78 %

04/06	EYEPOINT PHARMACEUTICALS, INC. : JPMorgan Chase da una recomendación de compra	ZM
08/05	EYEPOINT PHARMACEUTICALS, INC. : El Baird continua con su recomendación de compra	ZM

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference	05/06
EyePoint Pharmaceuticals : Investor Presentation May 2024	28/05
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	16/05
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q1 Revenue $11.7M	08/05
EyePoint Pharmaceuticals: Q1 Earnings Snapshot	08/05
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments	08/05
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
EyePoint Pharmaceuticals : PAVIA Topline Data Conference Call Presentation	06/05
Sector Update: Health Care Stocks Gain Pre-Bell Monday	06/05
EyePoint Pharmaceuticals Shares Fall After Diabetes Drug Fails to Meet Primary Endpoint	06/05
EyePoint Pharmaceuticals Shares Slide 32% on Duravyu Trial Missing Primary Endpoint	06/05
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy	06/05
EyePoint Pharmaceuticals, Inc. Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy	06/05
EyePoint Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	17/04
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	16/04
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists	02/04
EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board	02/04
EyePoint Pharmaceuticals : Investor Presentation March 2024	22/03
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	18/03
EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) added to S&P Pharmaceuticals Select Industry Index	18/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas EyePoint Pharmaceuticals, Inc. Deutsche Boerse AG

Acciones

PV3B

US30233G2093

Otros idiomas

Filtros